Drug intelligence / Profile preview

DV701B1.1-RNA

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

DV701B1.1-RNA is an investigational RNA-based immunostimulant vaccine developed for the prevention of HIV infection. It is being evaluated in a first-in-human, phase 1 clinical trial to assess its safety and immunogenicity, specifically targeting the V3 region of HIV as part of a novel vaccine strategy[3][8]. The drug was initially developed by the National Institute of Allergy & Infectious Diseases (NIAID)[1]. As an RNA therapy, it likely works by encoding antigens that stimulate an immune response against HIV.

Brand names: DV701B1.1-RNADV-701B1.1-RNADV 701B1.1-RNA
Other names: DV701B1.1-RNADV-701B1.1-RNADV 701B1.1-RNA

Targets

V3 loop (HIV-1 gp120 V3 loop)

Beyond the preview

Go deeper on DV701B1.1-RNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DV701B1.1-RNA.

Explore the full profile